CAS NO: | 1020412-43-4 |
包装 | 价格(元) |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
Cas No. | 1020412-43-4 |
别名 | 4-氨基-2-[(乙基氨基)甲基]-ALPHA,ALPHA-二甲基-1H-咪唑并[4,5-C]喹啉-1-乙醇 |
化学名 | 4-amino-2-[(ethylamino)methyl]-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol |
Canonical SMILES | NC1=NC2=C(C3=C1N=C(CNCC)N3CC(C)(O)C)C=CC=C2 |
分子式 | C17H23N5O |
分子量 | 313.4 |
溶解度 | ≤12mg/ml in ethanol;20mg/ml in DMSO;20mg/ml in dimethyl formamide |
储存条件 | Store at -20℃ |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
产品描述 | Gardiquimod is an agonist of human toll-like receptor 7 (TLR7) [1][2]. Toll-like receptors (TLRs) are a family of highly conserved pattern recognition receptors involved in innate immune responses to pathogen infection. TLR7 is highly expressed by plasmacytoid dendritic cells, and is also found on other leukocyte subpopulations. TLR7 and TLR8 recognize single-stranded RNA from viruses [4]. Gardiquimod is an agonist of human toll-like receptor 7 (TLR7), but not human TLR8, although it activates both porcine TLR7 and TLR8. In transfected 293T cells, Gardiquimod preferentially activated porcine TLR8 (pTLR8) [1]. Gardiquimod is a member of imidazoquinoline family. When codelivered intranasally with plant-derived Norwalk virus virus-like particles (NV VLPs), gardiquimod (GARD) induced NV VLP-specific serum IgG and IgG isotype responses and mucosal IgA responses in the gastrointestinal, respiratory, and reproductive tracts [3]. In macrophages and activated peripheral blood mononuclear cells (PBMCs) infected with X4, R5 or dual-tropic (R5/X4) strains of HIV-1, Gardiquimod inhibited HIV-1 reverse transcriptase and significantly reduced infection. Gardiquimod also induced interferon-alpha (IFN-a) transcription and sustained IFN-a protein secretion [4]. In BxPC-3 cells, Gardiquimod inhibited cell proliferation and migration, and induced apoptosis [5]. In C57BL/6 mice, Gardiquimod enhanced the ability of Treg cell to suppress the proliferation of Tresp cells. The CD4+CD25+Treg cells from mice that had received gardiquimod exhibited an increased inhibitory effect on anti-CD3/anti-CD28 mAb-coated bead-stimulated Tresp cells [2]. References: |